Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Dispatch

Ecologic Determinants of West Nile Virus Seroprevalence among Equids, Brazil

Edmilson F. de Oliveira-Filho1, Carlo Fischer1, Beatrice Sarah Berneck, Ianei O. Carneiro, Arne Kühne, Angelica C. de Almeida Campos, Jorge R.L. Ribas, Eduardo Martins Netto, Carlos Roberto Franke, Sebastian Ulbert, and Jan Felix DrexlerComments to Author 
Author affiliations: Charité-Universitätsmedizin Berlin, Berlin, Germany (E.F. de Oliveira-Filho, C. Fischer, A. Kühne, A.C. de Almeida Campos, J.F. Drexler); Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany (B.S. Berneck, S. Ulbert); Federal University of Bahia, Salvador, Brazil (I.O. Carneiro, E.M. Netto, C.R. Franke); Bahia State Agricultural Defense Agency, Salvador (J.R.L. Ribas); Sechenov University, Moscow, Russia (J.F. Drexler); German Centre for Infection Research, Berlin (J.F. Drexler)

Main Article

Table 1

West Nile virus seroprevalence per municipality, Brazil

Municipalities Sampling year(s) No. % Seroprevalence (95% CI)*
Antonio Cardoso 2015, 2016 10 0
Barreiras 2014, 2017, 2018 17 0
Caatiba 2018 19 0
Conceição do Jacuípe 2013 29 0
Conde 2013 28 3.6 (0.1–18.4)
Cotegipe 2013 11 0
Cristopolis 2013 10 0
Esplanada 2013 57 3.5 (0.4–12.1)
Eunápolis 2013, 2014 21 0
Feira de santana 2013 29 0
Formosa do Rio Preto 2013, 2017 37 0
Gongogi 2018 23 4.3 (0.1–21.9)
Ibotirama 2013 6 0
Igaporã 2013 27 0
Itabela 2013 6 0
Itabuna 2013, 2017 41 2.4 (0.1–12.9)
Itaju do Colônia 2013, 2015 6 0
Itapetinga 2018 14 7.1 (0.2–33.9)
Jaborandi 2017 5 20.0 (0.5–71.6)
Juazeiro 2013, 2017 49 2.0 (0.5–14.0)
Lauro de Freitas 2017 14 0
Mata de São João 2015, 2016, 2017 11 9.1 (0.2–41.3)
Mucuri 2013 13 0
Palmas de Monte Alto 2013 18 0
Riachão das Neves 2017, 2018 122 13.9 (8.3–21.4)
Rio Real 2013 25 0
Serra Dourada 2017 6 16.7 (0.4–64.1)
Ubaitaba 2018 7 42.9 (9.9–81.6)
Others†
 2013–2018
 52
 3.8 (0.5–13.2)
Total 2013–2018 713 4.5 (3.1–6.3)

*Seroprevalence is based on 90% endpoint plaque-reduction neutralization tests. †Detailed information, including municipalities with >5 serum samples, is available in Appendix Table 2).

Main Article

1These first authors contributed equally to this article.

Page created: June 29, 2021
Page updated: August 18, 2021
Page reviewed: August 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external